Heartflow, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Heartflow, Inc. (HTFL), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are HTFL insiders buying or selling?
In the last 12 months, Heartflow, Inc. insiders reported 1 open-market purchase ($1.1M) and 29 sales ($140.0M) — net selling of $139.0M. Since December 2025, Trabud has recorded 30 Form 4 filings for HTFL: 1 buys ($1.1M) and 29 sells ($140.0M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $1.1M by Jeffrey C Lightcap (Director) on Dec 17, 2025. SEC ↗
- The most recent open-market purchase was reported on Dec 17, 2025 (10 months ago).
Key Statistics (December 2025 – Oct 14, 2026)
Total Form 4 filings
30
SEC EDGAR
Insider filers
6
Insider buys (1)
$1.1M
Insider sells (29)
$140.0M
Insider sentiment
Net sellingNet insider flow of $139.0M in net selling since December 2025, and $139.0M in net selling over the last 12 months.
Recent HTFL insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 38.9K | $49.57 | $1.9M | SEC ↗ |
| Sep 21, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 19.7K | $50.15 | $987.1K | SEC ↗ |
| Sep 19, 2026 | Vikram Verghese | Chief Financial Officer | Sale | 24.3K | $50.55 | $1.2M | SEC ↗ |
| Sep 15, 2026 | Vikram Verghese | Chief Financial Officer | Sale | 35.0K | $50.08 | $1.8M | SEC ↗ |
| Sep 14, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 38.9K | $46.78 | $1.8M | SEC ↗ |
| Sep 10, 2026 | Vikram Verghese | Chief Financial Officer | Sale | 6.6K | $50.03 | $332.2K | SEC ↗ |
| Sep 4, 2026 | Vikram Verghese | Chief Financial Officer | Sale | 33.4K | $49.85 | $1.7M | SEC ↗ |
| Aug 25, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 27.2K | $50.00 | $1.4M | SEC ↗ |
| Aug 20, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 32.7K | $45.00 | $1.5M | SEC ↗ |
| Aug 20, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 9.2K | $41.23 | $380.1K | SEC ↗ |
| Aug 18, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 15.6K | $39.06 | $607.8K | SEC ↗ |
| Aug 12, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $28.31 | $638.7K | SEC ↗ |
| Jul 17, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 9.2K | $25.72 | $237.1K | SEC ↗ |
| Jul 14, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $27.75 | $626.1K | SEC ↗ |
| Jun 26, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 38.9K | $35.00 | $1.4M | SEC ↗ |
| Jun 12, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $28.50 | $643.0K | SEC ↗ |
| May 20, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 9.2K | $28.34 | $261.3K | SEC ↗ |
| May 13, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $29.12 | $657.0K | SEC ↗ |
| May 1, 2026 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Sale | 2.0M | $29.45 | $58.9M | SEC ↗ |
| Apr 14, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 22.6K | $26.72 | $602.9K | SEC ↗ |
| Apr 3, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 64.5K | $24.64 | $1.6M | SEC ↗ |
| Mar 23, 2026 | Campbell Rogers | Chief Medical Officer | Sale | 64.5K | $25.69 | $1.7M | SEC ↗ |
| Mar 20, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 9.7K | $25.00 | $243.1K | SEC ↗ |
| Mar 12, 2026 | John C.M. Farquhar | Chief Executive Officer | Sale | 12.8K | $22.66 | $290.9K | SEC ↗ |
| Mar 7, 2026 | Julie A Cullivan | Director | Sale | 9.1K | $25.00 | $228.1K | SEC ↗ |
Showing the 25 most recent of 30 Form 4 filings for Heartflow, Inc..
Most active HTFL insiders
- John C.M. Farquhar14 filings
- Campbell Rogers7 filings
- Vikram Verghese4 filings
- Bain Capital Life Sciences Investors, LLC2 filings
- Julie A Cullivan2 filings
Ask anything about HTFL insider activity
Use Trabud's AI agent to query Heartflow, Inc.'s Form 4 history in plain English — "Show me HTFL CEO purchases this year" or compare it against any other ticker.
Open the AI agentHTFL insider trading FAQ
Are Heartflow, Inc. insiders buying or selling?
In the last 12 months, Heartflow, Inc. insiders reported 1 open-market purchase ($1.1M) and 29 sales ($140.0M) — net selling of $139.0M. Since December 2025, Trabud has recorded 30 Form 4 filings for HTFL: 1 buys ($1.1M) and 29 sells ($140.0M). Over the full record that is net selling of $139.0M.
How many insiders trade HTFL stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Heartflow, Inc.. The most recent filing was accepted on Oct 14, 2026.
Where does Trabud get HTFL insider trading data?
All HTFL insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.